Evidence map›Paper›PMID 32578199›Full record

ArticleClinical and experimental immunology2020

The suppressive effect on CD4 T cell alloresponse against endothelial HLA-DR via PD-L1 induced by anti-A/B ligation.

K Iwasaki, H Hamana, H Kishi, T Yamamoto, T Hiramitsu, M Okad, T Tomosugi, A Takeda, S Narumi, Y Watarai and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

K IwasakiDepartment of Kidney Disease and Transplant Immunology, Aichi Medical University School of Medicine, Nagakute, Japan.ORCID 0000-0003-3229-5192
H HamanaDepartment of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
H KishiDepartment of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
T YamamotoDepartment of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
T HiramitsuDepartment of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
M OkadDepartment of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
T TomosugiDepartment of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
A TakedaDepartment of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
S NarumiDepartment of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Y WataraiDepartment of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Y MiwaDepartment of Kidney Disease and Transplant Immunology, Aichi Medical University School of Medicine, Nagakute, Japan.
M OkumuraDepartment of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Y MatsuokaDepartment of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
K HorimiDepartment of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
A MuraguchiDepartment of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
T KobayashDepartment of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Japanese Red Cross Nagoya Daini Hospital · JPAichi Medical University · JPUniversity of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While donor-specific human leukocyte antigen (HLA) antibodies are a frequent cause for chronic antibody-mediated rejection in organ transplantation, this is not the case for antibodies targeting blood group antigens, as ABO-incompatible (ABO-I) organ transplantation has been associated with a favorable graft outcome. Here, we explored the role of CD4 T cell-mediated alloresponses against endothelial HLA-D-related (DR) in the presence of anti-HLA class I or anti-A/B antibodies. CD4 T cells, notably CD45RA-memory CD4 T cells, undergo extensive proliferation in response to endothelial HLA-DR. The CD4 T cell proliferative response was enhanced in the presence of anti-HLA class I, but attenuated in the presence of anti-A/B antibodies. Microarray analysis and molecular profiling demonstrated that the expression of CD274 programmed cell death ligand 1 (PD-L1) increased in response to anti-A/B ligation-mediated extracellular signal-regulated kinase (ERK) inactivation in endothelial cells that were detected even in the presence of interferon-γ stimulation. Anti-PD-1 antibody enhanced CD4 T cell proliferation, and blocked the suppressive effect of the anti-A/B antibodies. Educated CD25

Indexed as

Organ TransplantationABO Blood-Group SystemB7-H1 AntigenEndothelial CellsGraft RejectionHLA-DR AntigensHumansIsoantibodiesT-Lymphocytes, RegulatoryABO Blood-Group SystemB7-H1 AntigenCD274 protein, humanHLA-DR AntigensIsoantibodiesaccommodationalloresponseantibody-mediated rejectionkidney transplantationPD-L1T cell receptor

Identifiers

PMID32578199
PMCPMC7597605
OpenAlexW3037513554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.